SeaSpine Announces Full Commercial Launch of Vu a∙POD Prime NanoMetalene System

SeaSpine Holdings Corporation, a developer of surgical solutions for the treatment of spinal disorders, announced the full commercial launch of its Vu a•POD Prime NanoMetalene System.

The Vu a•POD Prime NanoMetalene System features a zero-profile, standalone anterior lumbar interbody device that can be configured in a variety of footprint and lordosis combinations to accommodate an individual patient’s pathology. The Vu a•POD Prime NanoMetalene System offers multiple fixation options for maximum versatility and adds to SeaSpine’s portfolio of offerings featuring proprietary NanoMetalene technology.
 
“The new lordosis options enable me to better recreate the patient’s natural alignment. These features, particularly when combined with the NanoMetalene technology, should speed the healing process and improve long-term outcomes,” stated Dr. Nilesh Patel, an orthopedic surgeon practicing at Beaumont Hospital in Dearborn, Mich.
 
NanoMetalene interbody implants are designed to provide the benefits of a titanium surface while retaining the benefits associated with traditional PEEK (polyether ether ketone) devices, such as biocompatibility, a modulus of elasticity similar to bone, and excellent radiographic visibility for post-operative imaging. NanoMetalene describes a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK-OPTIMA polymer from INVIBIO. It is applied in a proprietary, high-energy, low-temperature process that differs from other coating applications and maximizes implant surface area with titanium nanotopography.
 
Additionally, Vu a•POD Prime NanoMetalene implants are delivered individually sterile-packaged and ready-to-use. This packaging solution is designed to facilitate configurations tailored to address individual surgeon preferences, while simplifying hospital processing requirements and inventory management. 
 
SeaSpine designs, develops, and commercializes surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes and cellular grafts that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal fusion hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. SeaSpine currently markets its products in the United States and in more than 30 countries worldwide.